Investorkonference Økonomisk Ugebrev


Per Plotnikof VP, Investor Relations

18 June 2025

ALK

ALK at a glance

ALK is a global specialty pharmaceutical company focused on allergy. ALK markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, the company is listed on Nasdaq Copenhagen



ALK is a growth company

Sustained revenue and earnings growth, enabling strong underlying cashflow generation



Note: Amounts in reported DKK, growth in local currency

ALK

Allergy is the most common chronic disease globally



500 million people globally have allergic rhinitis (AR)



100 million children globally have allergic rhinitis (AR)



200 million people globally have food allergy



20 million people in the EU alone at risk of anaphylaxis



Climate change Warmer weather, longer pollen seasons

The need for allergy solutions is only

growing in a changing world



Urbanisation

New ways of living, higher levels of air pollution




Food allergy on the rise Changing dietary habits, environmental factors

ALK

Expanding ALK's leadership in allergy

ALK's strategy aims at helping more people with allergies to a better life by unlocking the potential in existing markets and expanding into new therapy areas with high unmet needs



Allergy+ progress

Focus on high-potential growth levers

Respiratory allergy

- · Approvals of house dust mite and tree tablets for use in children
- Initial market response exceeded expectations
- Bridging trial in China to start in Q3, subject to approval
- Shionogi to acquire ALK's Japanese partner, Torii, in 2025

Anaphylaxis – neffy®

- Efforts on track in EU, the UK, and Canada. Imminent first launches
- New co-promotion agreement in the USA

Food allergy and new disease areas

- Ongoing phase II trial of peanut allergy tablet
- Phase IIb trial is being initiated with neffy® in chronic spontaneous urticaria







